Link Discovered Between Strep Infections and Blood Type
|
By LabMedica International staff writers Posted on 27 Apr 2017 |

Image: The Biacore T200 used for single-cycle kinetic surface plasmon resonance (Photo courtesy of GE Healthcare).
There are many different types of Streptococcal infection, from mild sore throats to deadly infections of the blood or organs and repeated infections can lead to chronic conditions, such as rheumatic heart disease.
Streptococcus pyogenes (group A streptococcus [GAS]) is responsible for over 500,000 deaths worldwide each year. The highly virulent M1T1 GAS clone is one of the most frequently isolated serotypes from streptococcal pharyngitis and invasive disease.
Scientists at the Illawarra Health and Medical Research Institute and their colleagues collected human buccal epithelial (HBE) cells, which were used to assess the role of blood group antigens in GAS attachment to host cells. Blood group status of 38 donors was determined via mass spectrometry of saliva samples from each donor. Unstimulated saliva and HBE cells were collected and prepared.
Streptococcus pyogenes (GAS) isolates were cultured overnight at 37 °C on horse blood agar or in static liquid cultures of Todd-Hewitt broth. Glycan microarray was employed to identify novel GAS-glycan interactions. After processing glycan microarray slides were dried by centrifugation, fluorescence intensity of array spots was measured using the ProScanArray microarray 4-Laser scanner. The interaction of M1 protein, M1 protein fragments and M1 peptides with specific glycan subsets was further investigated via single-cycle kinetic surface plasmon resonance (SPR) on a series S nitrilotriacetic acid (NTA) chip using a Biacore T200.
The scientists found that the association of M1T1 GAS with oral epithelial cells varied significantly as a result of phenotypic differences in blood group antigen expression, with significantly higher adherence to those cells expressing H antigen structures compared to cells expressing A, B, or AB antigen structures. These data suggest a novel mechanism for GAS attachment to host cells and propose a link between host blood group antigen expression and M1T1 GAS colonization. They found that found that people with blood group O could be more prone to infections caused by M1T1 GAS. The O blood group is the most common group among urban populations in western countries, including Australia.
Martina L. Sanderson-Smith, PhD, the senior author of the study said, “Rather than focusing on how Streptococcus spreads like other studies, we took a different approach. We know that some people are more susceptible to Streptococcal infections. We wanted to see if there are other biological reasons that increase the risks, and understand why some people suffer repeated infections.” The study was published on January 24, 2017, in the journal mBIO.
Streptococcus pyogenes (group A streptococcus [GAS]) is responsible for over 500,000 deaths worldwide each year. The highly virulent M1T1 GAS clone is one of the most frequently isolated serotypes from streptococcal pharyngitis and invasive disease.
Scientists at the Illawarra Health and Medical Research Institute and their colleagues collected human buccal epithelial (HBE) cells, which were used to assess the role of blood group antigens in GAS attachment to host cells. Blood group status of 38 donors was determined via mass spectrometry of saliva samples from each donor. Unstimulated saliva and HBE cells were collected and prepared.
Streptococcus pyogenes (GAS) isolates were cultured overnight at 37 °C on horse blood agar or in static liquid cultures of Todd-Hewitt broth. Glycan microarray was employed to identify novel GAS-glycan interactions. After processing glycan microarray slides were dried by centrifugation, fluorescence intensity of array spots was measured using the ProScanArray microarray 4-Laser scanner. The interaction of M1 protein, M1 protein fragments and M1 peptides with specific glycan subsets was further investigated via single-cycle kinetic surface plasmon resonance (SPR) on a series S nitrilotriacetic acid (NTA) chip using a Biacore T200.
The scientists found that the association of M1T1 GAS with oral epithelial cells varied significantly as a result of phenotypic differences in blood group antigen expression, with significantly higher adherence to those cells expressing H antigen structures compared to cells expressing A, B, or AB antigen structures. These data suggest a novel mechanism for GAS attachment to host cells and propose a link between host blood group antigen expression and M1T1 GAS colonization. They found that found that people with blood group O could be more prone to infections caused by M1T1 GAS. The O blood group is the most common group among urban populations in western countries, including Australia.
Martina L. Sanderson-Smith, PhD, the senior author of the study said, “Rather than focusing on how Streptococcus spreads like other studies, we took a different approach. We know that some people are more susceptible to Streptococcal infections. We wanted to see if there are other biological reasons that increase the risks, and understand why some people suffer repeated infections.” The study was published on January 24, 2017, in the journal mBIO.
Latest Hematology News
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
Channels
Clinical Chemistry
view channel
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
Selecting adjuvant therapy for early-stage hormone receptor-positive breast cancer depends on accurately assessing long-term risk of distant recurrence. Clinical features alone can leave uncertainty about... Read more
Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
Many cancers deviate from the normal chromosome number, but the clinical impact of extreme chromosome loss remains unclear. This widespread genomic disruption is associated with aggressive disease and... Read more
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








